Gland Pharma
Gland Pharma Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Company expects overall growth of 12%-13% as a minimum confidence level for FY '27 base business. - Mid-teens growth (around 15%) guidance remains, contingent on product launches and regulatory approvals, especially for Dalba in the U.S. - Dalba is approved in 6 European countries and launched in December; U.S. Gland Pharma targets a 15% organic CAGR over the next 5 years for base business growth.
From Gland Pharma's Q3 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Company expects overall growth of 12%-13% as a minimum confidence level for FY '27 base business.
- Mid-teens growth (around 15%) guidance remains, contingent on product launches and regulatory approvals, especially for Dalba in the U.S.
- Dalba is approved in 6 European countries and launched in December; U.S. approval expected in February, pending additional data submission.
- Additional demand from Europe expected to offset potential shortfalls in the U.S. Dalba launch.
- Cenexi shows strong momentum with 14%-21% revenue growth in FY ’26 and plans capacity expansions; aiming to maintain positive EBITDA and medium- to long-term growth.
- Capacity constraints in lyophilizers and liquid vials likely within 1-1.5 years, with ongoing investments to support volume growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Gland Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planned capex of approximately INR 2,000 crores over the next 5 years focused on:
- Brownfield expansions including new lines, lyophilizers, and additional warehouse capacity.
- Investment in BFS (Blow-Fill-Seal) technology lines.
- New ophthalmic line with suspension capability.
- Capex towards CDMO contracts.
- Next year capex expected to be more than INR 400 crores.
- Asset turn targeted at more than 3x due to high-value business expectations.
- Expansion driven by:
- Increased demand and expected growth.
- Current capacity constraints in lyophilizers and ophthalmic products.
- Need to stay ahead in emerging technology platforms (BFS).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gland Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Gland Pharma is experiencing higher volumes in the U.S., about 19% year-on-year increase, driven by new contracts signed, including GPO contracts.
- The company is in discussions with insulin manufacturers for significant orders to utilize the 40 million capacity pen cartridge line.
- For the new 100 million capacity line, expected to be ready by Q2 after validation, the existing signed contracts are sufficient to fill the capacity.
- There's a focus on CDMO contracts with commercial quantities and take-or-pay agreements, indicating clear revenue visibility over 2-3 years.
- Cenexi's annualized revenue is around EUR 200 million, with positive EBITDA expected going forward.
2 more points management made on order book & pipeline
Gland Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.7K Cr, net profit ₹367 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gland Pharma's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Shilpa Medicare Ltd (Q3 FY26)
Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income. Key concall takeaways from Shilpa Medicare's Q3 FY26…
- Sanofi India (Q3 FY26)
Diabetes portfolio is growing consistently, with insulin segment showing 6% full-year growth and double-digit growth in Q4 2025. Key concall takeaways from…
Frequently Asked Questions
What were Gland Pharma Q3 FY26 results?
Company expects overall growth of 12%-13% as a minimum confidence level for FY '27 base business. - Mid-teens growth (around 15%) guidance remains, contingent on product launches and regulatory approvals, especially for Dalba in the U.S. - Dalba is approved in 6 European countries and launched in December; U.S. Gland Pharma targets a 15% organic CAGR over the next 5 years for base business growth.
What is Gland Pharma share price analysis?
Gland Pharma currently shows a neutral. The stock trades at a P/E of 40.6 with a market cap of ₹46,509 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gland Pharma planning capital expenditure?
Planned capex of approximately INR 2,000 crores over the next 5 years focused on: - Brownfield expansions including new lines, lyophilizers, and additional warehouse capacity.
Keep Gland Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.